Spanish dermatology-focused pharma Almirall (BME: ALM) reported full-year 2025 net sales of 1.1 billion euros ($1.2 billion), ...

Atopic dermatitis, also known as eczema, is a chronic, inflammatory skin condition characterized by intense itching, dry skin, and recurrent flare-ups of red, inflamed lesions. It is driven by a ...

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial ...

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial executi ...

Please provide your email address to receive an email when new articles are posted on . “Clinician awareness of atopic comorbidities and the additional impact that these conditions have on patients ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Eli Lilly and Company LLY announced fourth-quarter and full-year results last week. The company delivered robust financial performance in 2025 with revenues of $65.2 billion rising 45% and EPS growing ...

Eli Lilly LLY announced that it entered a definitive agreement to acquire the privately held clinical-stage biotech Orna Therapeutics in a deal valued at $2.4 billion. This transaction includes both ...

Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest... ByInvesting.com • 10 Mar 2025 Eli Lilly’s EBGLYSS single monthly ...

Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading. The biotech, which went public late last year, ...